Resistance to PRMT5 Inhibitor Targeted Therapy in MCL [RNA-seq]
To identify the transcriptomic changes underlying acquired PRMT5 inhibitor resistance in MCL cell lines (n=3/group) and MCL PDX Overall design: RNA-sequencing of MCL PDX cells (untreated (n=3) short-term treated (n=3) and resistant treated (n=2)) and MCL cell lines resistant and sensitive treated (n=3) and untreated (n=3)